| 摘要 |
The present invention provides therapeutic agents for multiple sclerosis containing an antibody binding to macrophage migration inhibitory factor (MIF) as an active ingredient, and the therapeutic agents for multiple sclerosis of the present invention are effective for the conventional form of multiple sclerosis (C-MS) or the optic-spinal form of multiple sclerosis (OpS-Ms).
|
